TRIPASS XR تري باس

 

Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other

sedative regimens. Crit Care Med. 1998;26(5):947–956.

Mandelli M et al. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet. 1978;3(1):72–91.

Barr J et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the

intensive care unit. Crit Care Med. 2013;41(1):263–306.

Reade MC, Finfer S. Sedation and delirium in the intensive care unit. N EnglJ Med. 2014;370(5):444–454.

Chanques G et al. A prospective study of pain at rest: incidence and characteristics of an unrecognized symptom

in surgical and trauma versus medical intensive care unit patients. Anesthesiology. 2007;107(5):858–860.

Gélinas C. Management of pain in cardiac surgery ICU patients: have we improved over time? Intensive Crit

Care Nurs. 2007;23(5):298–303.

Stein-Parbury J, McKinley S. Patients’ experiences of being in an intensive care unit: a select literature review.

Am J Crit Care. 2000;9(1):20–27.

Schelling G et al. Exposure to high stress in the intensive care unit may have negative effects on health-related

quality-of-life outcomes after cardiac surgery. Crit Care Med. 2003;31(7):1971–1980.

Schelling G et al. Health-related quality of life and posttraumatic stress disorder in survivors of the acute

respiratory distress syndrome. Crit Care Med. 1998;26(4):651–659.

Erstad BL et al. Pain management principles in the critically ill. Chest. 2009;135(4):1075–1086.

Fraser GL et al. Frequency, severity, and treatment of agitation in young versus elderly patients in the ICU.

Pharmacotherapy. 2000;20(1):75–82.

Ryder-Lewis MC, Nelson KM. Reliability of the Sedation-Agitation Scale between nurses and doctors. Intensive

Crit Care Nurs. 2008;24(4): 211–217.

Ely EW et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond

Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983–2991.

Riker RR et al. Validating the Sedation-Agitation Scale with the Bispectral Index and Visual Analog Scale in adult

ICU patients after cardiac surgery. Intensive Care Med. 2001;27(5):853–858.

Girard TD et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically

ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial.

Lancet. 2008;371(9607):126–134.

Kress JP et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N

EnglJ Med. 2000;342(20): 1471–1477.

JacobiJ et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult.

Crit Care Med. 2002;30(1):119–141. Erratum in: Crit Care Med. 2002;30(3):726.

Payen JF et al. Current practices in sedation and analgesia for mechanically ventilated critically ill patients: a

prospective multicenter patient-based study. Anesthesiology. 2007;106(4):687–695.

Carson SS et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in

mechanically ventilated patients. Crit Care Med. 2006;34(5):1326–1332.

Barr J et al. Propofol dosing regimens for ICU sedation based upon an Integrated pharmacokineticpharmacodynamic model. Anesthesiology. 2001;95(2):324–333.

Tanios MA et al. Perceived barriers to the use of sedation protocols and daily sedation interruption: a

multidisciplinary survey. J Crit Care. 2009;24(1):66–73.

Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient

comfort in the intensive care unit. Pharmacotherapy. 2005;25(5, Pt 2):8S–18S.

Walder B et al. Seizure-like phenomena and propofol: a systematic review. Neurology. 2002;58(9):1327–1332.

Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des. 2004;10(29):3639–3649.

Fong JJ et al. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med.

2008;36(8):2281–2287.

Diedrich DA, Brown DR. Analytic reviews: propofol infusion syndrome in the ICU. J Intensive Care Med.

2011;26(2):59–72.

Merz TM et al. Propofol infusion syndrome – a fatal case at a low infusion rate. Anesth Analg. 2006;103(4):1050.

Chukwuemeka A et al. Short-term low-dose propofol anaesthesia associated with severe metabolic acidosis.

Anaesth Intensive Care. 2006;34(5):651–655.

Triltsch AE et al. Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective,

randomized, double blind, placebo-controlled phase II study. Crit Care Med. 2002;30(5):1007–1014.

Szumita PM et al. Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J

Health Syst Pharm. 2007;64(1):37–44.

Venn RM et al. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring

intensive care. Br J Anaesth. 2002;88(5):669–675.

Dasta JF et al. Comparing dexmedetomidine prescribing patterns and safety in the naturalistic setting versus

published data. Ann Pharmacother. 2004;38(7–8):1130–1135.

Sichrovsky TC et al. Dexmedetomidine sedation leading to refractory cardiogenic shock. Anesth Analg.

2008;106(6):1784–1786.

Riker RR et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA.

2009;301(5):489–499.

Shehabi Y et al. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and

cardiovascular effects. Intensive Care Med. 2004;30(12):2188–2196.

Pandharipande PP et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in

mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644–2653.

Venn M et al. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive

care unit. Intensive Care Med. 2003;29(2):201–207.

Martin E et al. The role of the alpha2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the

intensive care unit. J Intensive Care Med. 2003;18(1):29–41.

Young CC, Prielipp RC. Benzodiazepines in the intensive care unit. Crit Care Clin. 2001;17(4):843–862.

Pandharipande P et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit

patients. Anesthesiology. 2006;104(1):21–26.

Pisani MA et al. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older

population. Crit Care Med. 2009;37(1):177–183.

Spina SP, Ensom MH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients.

Pharmacotherapy. 2007;27(3):389–398.

Yaucher NE et al. Propylene glycol-associated renal toxicity from lorazepam infusion. Pharmacotherapy.

2003;23(9):1094–1099.

Yahwak JA et al. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene

glycol toxicity. Pharmacotherapy. 2008;28(8):984–991.

Gupta N et al. Delirium phenomenology: what can we learn from the symptoms of delirium? J Psychosom Res.

2008;65(3):215–222.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA:

American Psychiatric Association; 2013.

Milbrandt EB et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med.

2004;32(4):955–962.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

Shehabi Y et al. Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care

patients. Crit Care Med. 2010;38(12):2311–2318.

Pisani MA et al. Days of delirium are associated with 1-year mortality in an older intensive care unit population.

Am J Respir Crit Care Med. 2009;180(11):1092–1097.

Ely EW et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit.

JAMA. 2004;291(14):1753–1762.

Peterson JF et al. Delirium and its motoric subtypes: a study of 614 critically ill patients. J Am Geriatr Soc.

2006;54(3):479–484.

Ouimet S et al. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2007;33(1):66–

73.

Schweickert WD et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a

randomised controlled trial. Lancet. 2009;373(9678):1874–1882.

Needham DM et al. Early physical medicine and rehabilitation for patients with acute respiratory failure: a quality

improvement project. Arch Phys Med Rehabil. 2010;91(4):536–542.

Devlin JW et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter,

randomized, double-blind, placebo-controlled pilot study. Crit Care Med. 2010;38(2):419–427.

Jakob SM et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation:

two randomized controlled trials. JAMA. 2012;307(11):1151–1160.

Skillman JJ et al. Respiratory failure, hypotension, sepsis, and jaundice. A clinicalsyndrome associated with lethal

hemorrhage from acute stress ulceration of the stomach. Am J Surg. 1969;117(4):523–530.

Anderberg B, Sjödahl R. Prophylaxis and management of stress ulcers. Scand J Gastroenterol Suppl.

1985;110:101–104.

Shuman RB et al. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med.

1987;106(4):562–567.

Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care.

2005r;20(1):35–45.

Cook DJ et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials

Group. N EnglJ Med. 1994;330(6):377–381.

ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998.

ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. Am J Health Syst Pharm. 1999;56(4):347–379.

Guth PH. Mucosal coating agents and other nonantisecretory agents. Are they cytoprotective? Dig Dis Sci.

1987;32(6):647–654.

Cook DJ et al. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med. 1991;91(5):519–527.

Erratum in: Am J Med 1991;91(6):670.

Cook D et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in

patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med.

1998;338(12):791–797.

MacLaren R et al. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract

hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174(4):564–574.

Barkun AN et al. Proton pump inhibitors vs histamine 2 receptor antagonists for stress-related mucosal bleeding

prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507–520.

Alhazzani W et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in

critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693–705.

Bonten MJ et al. Continuous enteral feeding counteracts preventive measures for gastric colonization in intensive

care unit patients. Crit Care Med. 1994;22(6):939–944.

Eom CS et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis.

CMAJ. 2011;183(3):310–319.

Dial S et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficileassociated disease. JAMA. 2005;294(23):2989–2995.

McCowen KC et al. Stress-induced hyperglycemia. Crit Care Clin. 2001;17(1):107–124.

Yendamuri S et al. Admission hyperglycemia as a prognostic indicator in trauma. J Trauma. 2003;55(1):33–38.

Jeremitsky E et al. The impact of hyperglycemia on patients with severe brain injury. J Trauma. 2005;58(1):47–

50.

Falciglia M et al. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit

Care Med. 2009;37(12):3001–3009.

110.

111.

112.

113.

114.

115.

116.

117.

Bochicchio GV et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. J

Trauma. 2005;58(5):921–924. Erratum in:J Trauma. 2005;59(5):1277–1278.

Qaseem A et al; Clinical Guidelines Committee of the American College of Physicians. Use of intensive insulin

therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the

American College of Physicians. Ann Intern Med. 2011;154(4):260–267.

van den Berghe G et al. Intensive insulin therapy in critically ill patients. N EnglJ Med. 2001;345(19):1359–1367.

van den Berghe G et al. Intensive insulin therapy in the medical ICU. N EnglJ Med. 2006;354(5):449–461.

NICE-SUGAR Study Investigators, Finfer S, Chittock DR et al. Intensive versus conventional glucose control in

critically ill patients. N EnglJ Med. 2009;360(13):1283–1297.

COIITSS Study Investigators, Annane D, Cariou A et al. Corticosteroid treatment and intensive insulin therapy

for septic shock in adults: a randomized controlled trial. JAMA. 2010;303(4):341–348.

Brunkhorst FM et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med.

2008;358(2):125–139.

Preiser JC et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive

insulin therapy in adult intensive care units: the Glucontrolstudy. Intensive Care Med. 2009;35(10):1738–1748.

p. 1217

Multiple sclerosis (MS) is a chronic inflammatory and degenerative

disease of the central nervous system in which demyelination and

axonal damage occur. MS can take one of several forms: relapsingremitting, secondary-progressive, or primary-progressive are the most

common forms.

Case 57-1 (Questions 1, 5),

Figure 57-1

The diagnosis of MS is based on clinicalsymptoms and is supported by

magnetic resonance imaging (MRI) and laboratory testing

(cerebrospinal fluid oligoclonal bands and immunoglobulin G synthesis

rate; evoked potential testing). In an individual patient, dissemination in

space and time must be demonstrated before the diagnosis of MS is

made.

Case 57-1 (Questions 1, 5)

Glucocorticoids are the agents of choice for treatment of acute

MS relapses.

Case 57-1 (Question 7)

Clinically isolated syndrome (CIS) is a term used to describe a first

demyelinating neurologic event before the diagnosis of MS has been

made. When a patient presents with CIS and MRI abnormalities,

progression to clinically definite MS is likely, and therapy with interferon

β, glatiramer acetate, or teriflunomide helps to prevent this progression.

Case 57-1 (Questions 1, 2)

Dimethyl fumarate, glatiramer acetate, interferon β-1a, interferon β-1b,

and teriflunomide are potential first-line therapies for relapsing forms of

MS. The choice of treatment is often based on provider or patient

preference.

Case 57-1 (Questions 3, 5–8)

Case 57-2 (Question 1),

Table 57-3

Adherence to self-injection therapy with interferon β-1a, interferon β-1b,

and

glatiramer acetate is low.

Case 57-1 (Question 4),

Table 57-7

Alemtuzumab, fingolimod, mitoxantrone, and natalizumab therapy is

generally reserved for patients with worsening relapsing forms of MS

because of adverse effect concerns.

Case 57-1 (Question 7)

Case 57-2 (Question 3)

Patients with MS can experience many symptoms, such as walking

problems or impaired ambulation, sexual dysfunction, pain, bladder

dysfunction, fatigue, cognitive dysfunction, spasticity, bowel dysfunction,

dysphagia or dysarthria, and pseudobulbar affect. These symptoms may

require both nonpharmacologic and pharmacologic therapy.

Case 57-1 (Question 10),

Case 57-2 (Question 4),

Table 57-2 and 57-4

EPIDEMIOLOGY, NATURAL COURSE OF THE

DISEASE, AND PROGNOSIS

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the

central nervous system (CNS) in which demyelination and axonal damage occur.

1

The disease has a mean age at onset of 30 years, with diagnoses typically occurring

between the ages of 20 and 50 years.

2

,

3 Because of the young age at onset, MS has a

dramatic effect on employment and, in fact, is the most common cause of disability in

young adults.

4 Overall life expectancy is decreased by about 6 years compared with

age- and sex-matched control subjects,

5 and patients are three more likely to die than

the general population when matched for age and sex.

5

Infection and cardiac causes

of death are the most commonly reported, similar to a control population, but

occurring in higher frequencies in patients with MS.

5

,

6 Health-related quality of life

p. 1218

p. 1219

is lower in patients with MS than in the general population, and this decrease is

related to the severity of MS.

7

MS affects approximately 0.1% of the US population (400,000 people) and about

2.5 million people worldwide.

3

,

4 Women are 2 to 3 times more likely to have MS

than men.

3 Many environmental and genetic factors have been associated with MS

(Table 57-1); however, the causal nature of any of these factors has yet to be

established.

8–18 Current thought is that an environmental trigger acting in a genetically

susceptible individual is the probable cause of MS.

19

MS is most frequently encountered between 40 and 60 degrees north or south

latitude. Regions with a high prevalence include Western and Northern Europe,

Canada, Russia, Israel, Northern United States, New Zealand, and Southeast

Australia.

20 Additionally, relapse rates may also vary seasonally with latitude.

21 This

finding has spurred many research studies and hypotheses. One hypothesis is that

development of MS is related to sunlight exposure or vitamin D. Higher serum

concentrations of 25-hydroxyvitamin D (the major circulating form and the one that is

measured by clinical laboratory testing) are associated with reduced hazard of an MS

relapse, and lower concentrations are associated with higher rates of MS

diagnoses.

22

,

23 Genetically, lack of the vitamin D receptor (VDR) and CYP27B1

(encodes the enzyme responsible for vitamin D activation converting 25-hydroxylvitamin D to 1,25-hydroxyl-vitamin D) is associated with impaired immune system.

24

Some investigators have found links between season of birth and development of MS,

suggesting that maternal vitamin D status may be important.

24 Relapses also follow a

seasonal pattern, with peaks in the early spring and troughs in the autumn in both

hemispheres, further suggesting a role of vitamin D in relapses.

21

Epstein–Barr virus is a ubiquitous infection; however, high EBV titers and a

history of infectious mononucleosis both increase risk of developing MS. Smoking is

a risk factor, with higher levels of smoking conferring greater risk.

17

,

24 Dietary salt

intake may be associated with higher relapse rates and increased numbers of brain

lesions.

18

There is likely a genetic predisposition to development of MS. First-degree

relatives of people with MS have a risk of MS that is 10 to 25 times greater than the

general population; the concordance rate in identical twins is 35%.

11

,

13 There are

probably several genetic factors that increase risk for MS, including HLA type and

various single-nucleotide polymorphisms that control T-cell receptors, vitamin D

receptors, and estrogen receptors.

23

,

25

,

26 A specific major histocompatibility complex

(MHC) associated with MS is HLA-DRB1*1501 class II, but over 100 different

genetic variations have been associated with MS.

24 No genetic association has been

found for a particular clinical course or rate of progression.

24

Although MS is more prevalent in Caucasian populations in the United States,

there is evidence that African-American patients may be more likely to have primaryprogressive forms and may have a more severe disease course.

27–29

Table 57-1

Factors Associated with Multiple Sclerosis (MS)

Female sex

3,8 Low sun exposure

9,10

Caucasians

11 Low serum concentrations of vitamin D (25-

hydroxyvitamin D)

10

Higher latitudes of residence

12 Northern European heritage

13

High serum antibody titers to the Epstein–Barr virus

nuclear antigens

14,15

Tobacco smoking

14,16

Infectious mononucleosis

17 Dietary salt

18

MS is generally characterized as one of three main types according to the

presentation and clinical course of the disease: relapsing-remitting MS, secondaryprogressive MS, and primary-progressive MS. These three types of MS are

distinguished by their natural histories. Relapsing-remitting MS was named for the

relapses (also called exacerbations or attacks) of clinical disease activity that

alternate with periods of symptom remission. Recovery during the remission periods

can be complete, or the patient may continue to have some clinical deficits.

30

Between 80% and 90% of patients have relapsing-remitting MS when they are first

diagnosed.

1

,

31 Patient registry data provide insight regarding the prognosis of those

with relapsing-remitting MS. Patients diagnosed with relapsing-remitting MS at onset

have slower progression to disability than patients with primary-progressive MS;

patients having complete or near-complete recovery from the first attack of MS have

a longer time to disability compared with those with significant persistent deficits

after the first attack.

1

,

31

Approximately 80% of patients initially diagnosed with relapsing-remitting MS

experience a secondary-progressive form in which fewer relapses occur, but

disability continues to progress.

1

,

2 The cause of the conversion from relapsingremitting MS to secondary-progressive MS is unknown, but it has been hypothesized

that the change occurs when axonal loss in the CNS reaches a critical threshold.

32

The time to development of secondary-progressive MS is quite variable. The usual

time to conversion is 20 to 25 years after diagnosis, with a median patient age at the

time of conversion of 43 years; however, it may occur much sooner.

1

,

30

,

33

It is not

known how treatment affects this process. In one study, the number of early relapses

(within 2 years of diagnosis) was associated with a shorter time to development of

secondary-progressive MS.

34 Therefore, early treatment with a therapy that reduces

relapses might be expected to delay development of secondary-progressive MS.

Approximately 10% to 15% of patients have primary-progressive MS.

1

,

35 This

type of MS is progressive from onset with occasional minor improvements or

periods of stabilization.

30 Primary-progressive MS is more common in patients who

are older than 50 years at diagnosis.

1 Select studies have found this form to be more

common in men, but others have found no association with sex.

1

,

35 Mean time from

diagnosis to requiring a cane to walk is approximately 9 years for patients with

primary-progressive MS.

36

In the absence of treatment, patients who initially present with relapsing-remitting

MS develop average Expanded Disability Status Scale (EDSS) scores of 4.0 or

higher (indicating significant disability) by 7 years after diagnosis.

20 The EDSS is a

scale commonly used in MS to measure level of disability and progression of the

disease.

37 Some predictors of a more progressive disease course include male

gender, multisystem symptoms, incomplete recovery from the initial episode,

progressive disease from the time of diagnosis, older age at onset, and abnormal

baseline magnetic resonance imaging (MRI) results.

30